INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Summit Therapeutics Inc. and its officers or directors following disappointing clinical trial results for its drug ivonescimab [1][3]. Group 1: Clinical Trial Results - On May 30, 2025, Summit announced topline results from the Phase III clinical trial, HARMONi, which evaluated ivonescimab [3]. - Patients treated with ivonescimab and chemotherapy were 48% less likely to progress or die compared to those receiving chemotherapy alone, but the drug did not show a statistically significant difference in overall survival [3]. Group 2: Stock Market Reaction - Following the announcement of the clinical trial results, Summit's stock price fell by $7.99 per share, representing a 30.5% decline, closing at $18.22 per share on May 30, 2025 [4].